Evidence map›Paper›PMID 25690786›Full record

ArticleBioorganic & medicinal chemistry letters2015

Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.

Mohit P Mathew, Elaine Tan, Christopher T Saeui, Patawut Bovonratwet, Lingshu Liu, Rahul Bhattacharya, Kevin J Yarema

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Altered glycosylation in pancreatic cancer and beyond.The Journal of experimental medicine · 2022
    Review
  5. Article
  6. The Applications of Metabolic Glycoengineering.Frontiers in cell and developmental biology · 2022
    Review
  7. Article
  8. Evaluating the Role of Galectins in Clathrin-Independent Endocytosis.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  9. Article
  10. Review
  11. Glycosylation and raft endocytosis in cancer.Cancer metastasis reviews · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mohit P MathewDepartment of Biomedical Engineering and the Translational Tissue Engineering Center, The Johns Hopkins University, 5029 Robert H. & Clarice Smith Building, 400 North Broadway, Baltimore, MD 21231, USA.
Elaine TanDepartment of Biomedical Engineering and the Translational Tissue Engineering Center, The Johns Hopkins University, 5029 Robert H. & Clarice Smith Building, 400 North Broadway, Baltimore, MD 21231, USA.
Christopher T SaeuiDepartment of Biomedical Engineering and the Translational Tissue Engineering Center, The Johns Hopkins University, 5029 Robert H. & Clarice Smith Building, 400 North Broadway, Baltimore, MD 21231, USA.
Patawut BovonratwetDepartment of Biomedical Engineering and the Translational Tissue Engineering Center, The Johns Hopkins University, 5029 Robert H. & Clarice Smith Building, 400 North Broadway, Baltimore, MD 21231, USA.
Lingshu LiuDepartment of Biomedical Engineering and the Translational Tissue Engineering Center, The Johns Hopkins University, 5029 Robert H. & Clarice Smith Building, 400 North Broadway, Baltimore, MD 21231, USA.
Rahul BhattacharyaDepartment of Biomedical Engineering and the Translational Tissue Engineering Center, The Johns Hopkins University, 5029 Robert H. & Clarice Smith Building, 400 North Broadway, Baltimore, MD 21231, USA.
Kevin J YaremaDepartment of Biomedical Engineering and the Translational Tissue Engineering Center, The Johns Hopkins University, 5029 Robert H. & Clarice Smith Building, 400 North Broadway, Baltimore, MD 21231, USA. Electronic address: kyarema1@jhu.edu.
Johns Hopkins University · US

Funding

Probing the Connections between Monosaccharide Analogs, Sialic Acid Metabolism, aR01CA112314 · NCI · JOHNS HOPKINS UNIVERSITY · PI YAREMA, KEVIN J · 2005 to 2022
$4.5M
NCI NIH HHS R01 CA112314NCI NIH HHS R01CA112314
6 · The paper itself

Abstract

Metastatic human pancreatic cancer cells (the SW1990 line) that are resistant to the EGFR-targeting tyrosine kinase inhibitor drugs (TKI) erlotinib and gefitinib were treated with 1,3,4-O-Bu3ManNAc, a 'metabolic glycoengineering' drug candidate that increased sialylation by ∼2-fold. Consistent with genetic methods previously used to increase EGFR sialylation, this small molecule reduced EGF binding, EGFR transphosphorylation, and downstream STAT activation. Significantly, co-treatment with both the sugar pharmacophore and the existing TKI drugs resulted in strong synergy, in essence re-sensitizing the SW1990 cells to these drugs. Finally, 1,3,4-O-Bu3ManNAz, which is the azido-modified counterpart to 1,3,4-O-Bu3ManNAc, provided a similar benefit thereby establishing a broad-based foundation to extend a 'metabolic glycoengineering' approach to clinical applications.

Indexed as

Metabolic EngineeringAntineoplastic AgentsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmDrug SynergismErbB ReceptorsErlotinib HydrochlorideGefitinibGlycosylationHumansPancreatic NeoplasmsPhosphorylationProtein Kinase InhibitorsQuinazolinesSTAT Transcription FactorsAntineoplastic AgentsErbB ReceptorsErlotinib HydrochlorideGefitinibProtein Kinase InhibitorsQuinazolinesSTAT Transcription FactorsDrug synergyEpidermal growth factor receptorMetabolic oligosaccharide engineeringPancreatic cancerReceptor tyrosine kinase inhibitorSialylation

Identifiers

PMID25690786
PMCPMC5753412
OpenAlexW1982002770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.